97016 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
Sub-classes:METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS
#2MELANOCORTIN RECEPTOR LIGANDS
#3NEUROPEPTIDE-EXPRESSING VECTORS AND METHODS FOR THE TREATMENT OF EPILEPSY
#4PEPTIDES AND USES THEREOF
#5MELANOCORTIN RECEPTOR LIGANDS
#6NEUROPEPTIDE-EXPRESSING VECTORS AND METHODS FOR THE TREATMENT OF EPILEPSY
#7Melanocortin Receptor Ligands
#8METHODS AND COMPOSITIONS RELATED TO IMPROVING PROPERTIES OF PHARMACOLOGICAL AGENTS TARGETING NERVOUS SYSTEM
#9STABILIZED BIOACTIVE PEPTIDES AND METHODS OF IDENTIFICATION, SYNTHESIS, AND USE
#10Melanocortin Receptor Ligands
#11MU OPIOID RECEPTOR AGONIST ANALOGS OF THE ENDOMORPHINS
#12MU OPIOID RECEPTOR AGONIST ANALOGS OF THE ENDOMORPHINS
#13Mu opioid receptor agonist analogs of the endomorphins
#14Delta receptor agonist peptides and use thereof
#15Opioid peptide
#16Stabilizied bioactive peptides and methods of identification, synthesis and use
#17Non-cytotoxic protein conjugates
#18Melanocortin Receptor Ligands
#19Dynorphin A analogs with bradykinin receptors specificity for modulation of neuropathic pain
#20Albumin fusion proteins
#21Methods and compositions related to improving properties of pharmacological agents targeting nervous system
#22Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
#23Non-cytotoxic protein conjugates
#24Non-cytotoxic protein conjugates
#25Methods and compositions related to improving properties of pharmacological agents targeting nervous system
#26CAFFEOYLALPHANEOENDORPHIN PEPTIDE DERIVATIVE AND USE THEREOF AS ANTI-ITCHING AND ANTI-ATOPIC AGENTS
#27OPIOID PEPTIDE ESTERS AND METHODS OF USE
#28Mu opioid receptor agonist analogs of the endomorphins
#29Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
#30Fusion proteins
#31Stabilized melanocortin ligands
#32Non-cytotoxic protein conjugates
#33Treatment of pain
#34Caged Neuropeptides: modulation and measurement of synapse and signaling activity; and methods for drug evaluation, pharmaceuticals preparation and treatment
#35Use of Melanocortins to Treat Dyslipidemia
#36Method for enucleating nucleated erythrocyte, and enucleation inducer
#37Stabilized bioactive peptides and methods of identification, synthesis, and use
#38Non-cytotoxic protein conjugates
#39Albumin fusion proteins
#40PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS
#41Methods and compositions for treating conditions
#42Melanocortin receptor ligands
#43Octapeptide compounds derived from somatostatin and the therapeutic use thereof
#44FUSION PROTEINS
#45Albumin fusion proteins
#46Melanocortin receptor ligands
#47Highly potent full and partial agonists and antagonists of the nociceptin/orphanin FQ receptor
#48Conjugates of membrane translocating agents and pharmaceutically active agents
#49Methods and compositions for treating conditions
#50COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
#51Cyclic peptide compositions for treatment of sexual dysfunction
#52TREATMENT OF PAIN
#53Methods and compositions related to improving properties of pharmacological agents targeting nervous system
#54Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes
#55Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
#56Albumin Fusion Proteins
#57Albumin Fusion Proteins
#58Stabilized bioactive peptides and methods of identification, synthesis, and use
#59Methods for the synthesis of cyclic peptides
#60Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
#61Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
#62Nociceptin-based analgesics
#63Albumin fusion proteins
#64Method for screening for agents that affect food intake
#65Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
#66Albumin Fusion Proteins
#67Albumin fusion proteins comprising insulin polypeptides
#68Albumin Fusion Proteins
#69G-CSF-albumin fusion proteins
#70Albumin fusion proteins
#71Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
#72Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
#73Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
#74Albumin fusion proteins
#75Methods for modulating activities in plants
#76Albumin fusion proteins
#77GENES ASSOCIATED WITH OBESITY AND METHODS FOR USING THE SAME
#78Method of treating condition in animal
#79Methods for the synthesis of arginine-containing peptides
#80Upstream control elements of the proopiomelanocortin gene and their use
#81Albumin fusion proteins
#82Melanocortin Metallopeptode Combinatorial Libraries and Applications
#83Nociceptin-based analgesics
#84Albumin fusion proteins
#85Methods and compositions for modulating conditions in both mammals and plants
#86Cyclic peptide compositions for treatment of sexual dysfunction
#87Conjugates of membrane translocating agents and pharmaceutically active agents
#88Stabilized bioactive peptides and methods of identification, synthesis, and use
#89Composition and method for regulation of body weight and associated conditions
#90Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
#91Nucleic acid and polypeptide linked to breast cancer and uses therefor
#92Diuretic peptide conjugates
#93Albumin fusion proteins comprising GLP-1 polypeptides
#94Conjugates of membrane translocating agents and pharmaceutically active agents
#95Genes associated with obesity and methods for using the same
#96Affinity markers for human serum albumin
#97Composition and method for regulation of body weight and associated conditions
#98Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
#99Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone